Zhao Mingkun, Zhu Guanghui, Zhuang Aobo, Tong Hanxing, Fang Yuan, Zhang Yong
Department of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Department of Gastrointestinal Surgery, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine.
J Clin Transl Res. 2022 Aug 12;8(5):339-343. eCollection 2022 Oct 31.
There are lacking standard treatment guidelines for aggressive fibromatosis (AF) because of its rarity.
This study aimed to investigate the risk factors for recurrence and survival of abdominal AF after radical surgical resection.
From August 2012 to December 2020, a retrospective analysis was conducted on the clinical data of 69 AF in Shanghai Public Health Clinical Center Affiliated to Fudan University, with the tumor locating either in the abdominal wall or in the abdominal cavity. The main observation end point was progression-free survival time (PFS) and overall survival time (OS).
All 69 patients achieved microscopic R0 resection, 10 (14.5%) had local recurrence, and 3 (4.3%) died. The PFS rate after 1, 3, 5, and 10 years was 96.8%, 87.7%, 78.8%, and 78.8%, respectively. The OS rate after 1, 3, 5, and 10 years was 100%, 100%, 92.9%, and 81.3%, respectively. In 10 patients with recurrence, the median recurrence time was 17.6 months. Concomitant familial adenomatous polyposis (FAP) and history of previous recurrence were independent risk factors of post-operative recurrence.
After radical surgery of abdominal AF, the local recurrence rate was 15%. Concomitant FAP and a previous history of recurrence were independent risk factors of post-operative recurrence. R0 and a combined organ resection should be performed especially in FAP patients to minimize the recurrence and improve the prognosis.
The present study identifies the risk factors of recurrence in AF and suggests R0 resection especially in concomitant FAP patients. A wait-and-see strategy should not be generally implemented and radical surgery will bring clinical benefits to patients with such kind of rare disease.
侵袭性纤维瘤病(AF)较为罕见,因此缺乏标准治疗指南。
本研究旨在探讨根治性手术切除后腹部AF复发和生存的危险因素。
回顾性分析2012年8月至2020年12月复旦大学附属上海公共卫生临床中心69例AF患者的临床资料,肿瘤位于腹壁或腹腔。主要观察终点为无进展生存时间(PFS)和总生存时间(OS)。
69例患者均实现显微镜下R0切除,10例(14.5%)局部复发,3例(4.3%)死亡。1年、3年、5年和10年的PFS率分别为96.8%、87.7%、78.8%和78.8%。1年、3年、5年和10年的OS率分别为100%、100%、92.9%和81.3%。10例复发患者的中位复发时间为17.6个月。合并家族性腺瘤性息肉病(FAP)和既往复发史是术后复发的独立危险因素。
腹部AF根治性手术后,局部复发率为15%。合并FAP和既往复发史是术后复发的独立危险因素。尤其在FAP患者中应进行R0切除及联合器官切除,以减少复发并改善预后。
本研究确定了AF复发的危险因素,并建议尤其是合并FAP的患者进行R0切除。一般不应采取观望策略,根治性手术将给这类罕见病患者带来临床益处。